PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
100.00%
Positive gross profit growth while AGEN is negative. John Neff would see a clear operational edge over the competitor.
-2.59%
Negative EBIT growth while AGEN is at 4.36%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-2.59%
Negative operating income growth while AGEN is at 5.91%. Joel Greenblatt would press for urgent turnaround measures.
-10.34%
Negative net income growth while AGEN stands at 29.92%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-10.26%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-10.26%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.08%
Slight or no buybacks while AGEN is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.08%
Slight or no buyback while AGEN is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-93.84%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-94.42%
Negative FCF growth while AGEN is at 2.13%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.91%
Positive long-term OCF/share growth while AGEN is negative. John Neff would see a structural advantage in sustained cash generation.
68.32%
Positive OCF/share growth while AGEN is negative. John Neff might see a comparative advantage in operational cash viability.
41.88%
Positive 3Y OCF/share CAGR while AGEN is negative. John Neff might see a big short-term edge in operational efficiency.
55.55%
Positive 10Y CAGR while AGEN is negative. John Neff might see a substantial advantage in bottom-line trajectory.
79.95%
Positive 5Y CAGR while AGEN is negative. John Neff might view this as a strong mid-term relative advantage.
56.07%
Positive short-term CAGR while AGEN is negative. John Neff would see a clear advantage in near-term profit trajectory.
188.20%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-69.82%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
327.49%
Positive short-term equity growth while AGEN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.65%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-14.02%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-4.69%
We’re deleveraging while AGEN stands at 11.89%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
7.04%
We increase R&D while AGEN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-5.63%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.